 Mina Pantcheva
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 20 | 2025 | 219 | 4.160 |
Why?
| | Glaucoma, Open-Angle | 8 | 2023 | 103 | 2.910 |
Why?
| | Ocular Hypertension | 7 | 2022 | 64 | 2.890 |
Why?
| | Intraocular Pressure | 22 | 2025 | 299 | 2.410 |
Why?
| | Phacoemulsification | 9 | 2025 | 117 | 2.140 |
Why?
| | Trabeculectomy | 7 | 2025 | 73 | 2.050 |
Why?
| | Uveitis | 3 | 2022 | 128 | 1.940 |
Why?
| | Trabecular Meshwork | 7 | 2024 | 79 | 1.490 |
Why?
| | Visual Acuity | 7 | 2024 | 323 | 1.420 |
Why?
| | Laser Coagulation | 4 | 2023 | 57 | 1.320 |
Why?
| | Uveitis, Anterior | 2 | 2019 | 13 | 1.250 |
Why?
| | Cataract | 7 | 2023 | 197 | 1.180 |
Why?
| | Cataract Extraction | 5 | 2024 | 97 | 1.140 |
Why?
| | Ciliary Body | 3 | 2018 | 33 | 0.930 |
Why?
| | Endoscopy | 3 | 2018 | 269 | 0.780 |
Why?
| | Fibronectins | 3 | 2021 | 119 | 0.750 |
Why?
| | Glycosaminoglycans | 2 | 2022 | 85 | 0.720 |
Why?
| | Chondroitin Sulfates | 2 | 2020 | 34 | 0.720 |
Why?
| | Retinal Ganglion Cells | 6 | 2022 | 97 | 0.670 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.630 |
Why?
| | Corneal Injuries | 3 | 2024 | 41 | 0.630 |
Why?
| | Tissue Scaffolds | 2 | 2020 | 197 | 0.610 |
Why?
| | Collagen | 2 | 2020 | 437 | 0.610 |
Why?
| | Mustard Gas | 3 | 2024 | 130 | 0.580 |
Why?
| | Chemical Warfare Agents | 3 | 2024 | 133 | 0.580 |
Why?
| | Biocompatible Materials | 2 | 2020 | 395 | 0.550 |
Why?
| | Disease Management | 1 | 2019 | 597 | 0.500 |
Why?
| | Epithelial-Mesenchymal Transition | 4 | 2021 | 197 | 0.450 |
Why?
| | Tonometry, Ocular | 6 | 2021 | 88 | 0.440 |
Why?
| | Tomography, Optical Coherence | 2 | 2019 | 187 | 0.430 |
Why?
| | Lens, Crystalline | 3 | 2021 | 100 | 0.420 |
Why?
| | Prostaglandins F | 1 | 2011 | 17 | 0.380 |
Why?
| | Retrospective Studies | 13 | 2025 | 14675 | 0.350 |
Why?
| | Risk Assessment | 1 | 2019 | 3310 | 0.320 |
Why?
| | Nerve Fibers | 1 | 2009 | 89 | 0.320 |
Why?
| | Capsule Opacification | 2 | 2020 | 21 | 0.310 |
Why?
| | Transforming Growth Factor beta2 | 2 | 2021 | 33 | 0.310 |
Why?
| | Epithelial Cells | 3 | 2021 | 1075 | 0.310 |
Why?
| | Postoperative Complications | 2 | 2022 | 2511 | 0.300 |
Why?
| | Humans | 39 | 2025 | 130305 | 0.290 |
Why?
| | Postoperative Period | 5 | 2025 | 325 | 0.280 |
Why?
| | Inflammation | 1 | 2018 | 2721 | 0.270 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2007 | 56 | 0.270 |
Why?
| | Eye | 2 | 2006 | 104 | 0.270 |
Why?
| | Refraction, Ocular | 2 | 2024 | 36 | 0.260 |
Why?
| | Treatment Outcome | 7 | 2025 | 10341 | 0.250 |
Why?
| | Stents | 3 | 2021 | 523 | 0.240 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 223 | 0.240 |
Why?
| | Cornea | 4 | 2024 | 117 | 0.240 |
Why?
| | Glaucoma Drainage Implants | 2 | 2021 | 48 | 0.240 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.240 |
Why?
| | Aged | 14 | 2025 | 22282 | 0.230 |
Why?
| | Gelatin | 1 | 2024 | 41 | 0.230 |
Why?
| | Lens Implantation, Intraocular | 3 | 2022 | 59 | 0.220 |
Why?
| | Aged, 80 and over | 7 | 2025 | 7128 | 0.220 |
Why?
| | Photorefractive Keratectomy | 1 | 2024 | 19 | 0.220 |
Why?
| | Lasers, Excimer | 1 | 2024 | 29 | 0.220 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2024 | 22 | 0.220 |
Why?
| | Printing, Three-Dimensional | 1 | 2024 | 85 | 0.220 |
Why?
| | Iritis | 1 | 2023 | 2 | 0.210 |
Why?
| | Macular Edema | 1 | 2023 | 42 | 0.210 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2022 | 56 | 0.200 |
Why?
| | Antihypertensive Agents | 2 | 2016 | 489 | 0.190 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2021 | 30 | 0.190 |
Why?
| | Kynurenine 3-Monooxygenase | 1 | 2020 | 4 | 0.170 |
Why?
| | Kynurenic Acid | 1 | 2020 | 17 | 0.170 |
Why?
| | Posterior Capsule of the Lens | 1 | 2020 | 11 | 0.170 |
Why?
| | Hepatitis C | 1 | 2022 | 235 | 0.170 |
Why?
| | Ophthalmology | 1 | 2001 | 82 | 0.160 |
Why?
| | Follow-Up Studies | 4 | 2025 | 4961 | 0.160 |
Why?
| | Animals | 17 | 2024 | 35076 | 0.160 |
Why?
| | Disease Models, Animal | 5 | 2022 | 4044 | 0.160 |
Why?
| | Male | 18 | 2025 | 63748 | 0.160 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 174 | 0.150 |
Why?
| | Aldehyde Reductase | 1 | 2018 | 27 | 0.150 |
Why?
| | Prosthesis Implantation | 2 | 2018 | 149 | 0.150 |
Why?
| | Rabbits | 3 | 2024 | 766 | 0.150 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 16 | 0.150 |
Why?
| | Middle Aged | 10 | 2025 | 31322 | 0.150 |
Why?
| | Dexamethasone | 3 | 2024 | 337 | 0.140 |
Why?
| | Hydrogels | 1 | 2024 | 637 | 0.140 |
Why?
| | Reperfusion Injury | 1 | 2020 | 276 | 0.140 |
Why?
| | Risk Factors | 3 | 2022 | 9865 | 0.140 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 345 | 0.130 |
Why?
| | Aspirin | 1 | 2020 | 383 | 0.130 |
Why?
| | Microscopy, Electron, Scanning | 2 | 2007 | 194 | 0.130 |
Why?
| | Stem Cells | 1 | 2001 | 585 | 0.130 |
Why?
| | Female | 13 | 2025 | 68842 | 0.130 |
Why?
| | Filtering Surgery | 1 | 2016 | 22 | 0.130 |
Why?
| | Perception | 1 | 2018 | 339 | 0.120 |
Why?
| | Crystallins | 1 | 2016 | 51 | 0.120 |
Why?
| | Glaucoma, Neovascular | 1 | 2015 | 10 | 0.120 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 109 | 0.120 |
Why?
| | Drug Packaging | 1 | 2015 | 42 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 832 | 0.120 |
Why?
| | Histones | 1 | 2020 | 589 | 0.120 |
Why?
| | Actins | 3 | 2024 | 409 | 0.110 |
Why?
| | Patient Preference | 1 | 2016 | 183 | 0.110 |
Why?
| | Caspases | 3 | 2005 | 249 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 645 | 0.100 |
Why?
| | Incidence | 1 | 2019 | 2657 | 0.100 |
Why?
| | Ophthalmic Solutions | 3 | 2018 | 74 | 0.100 |
Why?
| | Axial Length, Eye | 2 | 2024 | 15 | 0.090 |
Why?
| | Mice | 7 | 2022 | 16832 | 0.090 |
Why?
| | Corneal Edema | 1 | 2010 | 3 | 0.090 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 1 | 2010 | 6 | 0.090 |
Why?
| | Swine | 2 | 2016 | 744 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 577 | 0.090 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2009 | 38 | 0.080 |
Why?
| | Visual Fields | 1 | 2009 | 87 | 0.080 |
Why?
| | Cell Culture Techniques | 2 | 2024 | 352 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 5400 | 0.080 |
Why?
| | Adult | 6 | 2025 | 35711 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2020 | 2811 | 0.070 |
Why?
| | Sclera | 1 | 2007 | 36 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1983 | 0.070 |
Why?
| | Intravitreal Injections | 2 | 2018 | 55 | 0.070 |
Why?
| | Prospective Studies | 4 | 2021 | 7131 | 0.070 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 34 | 0.070 |
Why?
| | Autopsy | 1 | 2006 | 90 | 0.070 |
Why?
| | Optic Nerve | 1 | 2006 | 65 | 0.060 |
Why?
| | Young Adult | 2 | 2019 | 12404 | 0.060 |
Why?
| | United States | 2 | 2023 | 14110 | 0.060 |
Why?
| | Optic Nerve Injuries | 1 | 2005 | 5 | 0.060 |
Why?
| | Administration, Topical | 2 | 2016 | 148 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 7 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 17 | 0.060 |
Why?
| | Preoperative Period | 2 | 2019 | 113 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 83 | 0.060 |
Why?
| | Refractive Errors | 1 | 2024 | 18 | 0.060 |
Why?
| | Tacrolimus | 1 | 2005 | 147 | 0.060 |
Why?
| | Methacrylates | 1 | 2024 | 112 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2024 | 4106 | 0.060 |
Why?
| | Irritants | 1 | 2024 | 46 | 0.050 |
Why?
| | Myopia | 1 | 2024 | 48 | 0.050 |
Why?
| | Perfusion | 1 | 2024 | 192 | 0.050 |
Why?
| | Mechlorethamine | 1 | 2024 | 66 | 0.050 |
Why?
| | Postoperative Care | 1 | 2025 | 246 | 0.050 |
Why?
| | Adolescent | 2 | 2019 | 20374 | 0.050 |
Why?
| | Loteprednol Etabonate | 1 | 2023 | 6 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 104 | 0.050 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2003 | 27 | 0.050 |
Why?
| | Acetazolamide | 1 | 2023 | 24 | 0.050 |
Why?
| | Triamcinolone Acetonide | 1 | 2023 | 28 | 0.050 |
Why?
| | Axonal Transport | 1 | 2022 | 25 | 0.050 |
Why?
| | Laminin | 1 | 2022 | 70 | 0.050 |
Why?
| | Neuroprotection | 1 | 2022 | 33 | 0.050 |
Why?
| | Rats | 4 | 2022 | 5285 | 0.050 |
Why?
| | Blindness | 1 | 2022 | 38 | 0.050 |
Why?
| | Cell Line | 2 | 2020 | 2786 | 0.050 |
Why?
| | Retinal Detachment | 1 | 2003 | 57 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2024 | 375 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 151 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2022 | 133 | 0.050 |
Why?
| | Algorithms | 1 | 2009 | 1638 | 0.050 |
Why?
| | Ligands | 1 | 2024 | 624 | 0.050 |
Why?
| | Intraoperative Complications | 1 | 2022 | 134 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 453 | 0.050 |
Why?
| | Molecular Chaperones | 1 | 2022 | 174 | 0.050 |
Why?
| | Manometry | 1 | 2021 | 92 | 0.050 |
Why?
| | Signal Transduction | 3 | 2021 | 4930 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 235 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 708 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2024 | 509 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2020 | 82 | 0.040 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2020 | 95 | 0.040 |
Why?
| | Rats, Inbred BN | 3 | 2005 | 53 | 0.040 |
Why?
| | Caspase 9 | 3 | 2005 | 54 | 0.040 |
Why?
| | Circadian Rhythm | 1 | 2023 | 404 | 0.040 |
Why?
| | Acetylation | 1 | 2020 | 237 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 5365 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2022 | 500 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 14 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.040 |
Why?
| | Histological Techniques | 1 | 2018 | 41 | 0.040 |
Why?
| | Enzyme Activation | 3 | 2005 | 817 | 0.040 |
Why?
| | Proteomics | 1 | 2024 | 1008 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 673 | 0.030 |
Why?
| | Microscopy | 1 | 2018 | 140 | 0.030 |
Why?
| | Cadherins | 1 | 2018 | 189 | 0.030 |
Why?
| | Porosity | 1 | 2016 | 94 | 0.030 |
Why?
| | Cell Count | 2 | 2010 | 320 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 526 | 0.030 |
Why?
| | Snail Family Transcription Factors | 1 | 2016 | 17 | 0.030 |
Why?
| | Smad3 Protein | 1 | 2016 | 44 | 0.030 |
Why?
| | Smad2 Protein | 1 | 2016 | 37 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 962 | 0.030 |
Why?
| | Smad4 Protein | 1 | 2016 | 37 | 0.030 |
Why?
| | Biomimetic Materials | 1 | 2016 | 72 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 5083 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 529 | 0.030 |
Why?
| | Registries | 1 | 2023 | 1934 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 97 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 607 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 948 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3069 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 981 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1565 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2107 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 2 | 2003 | 127 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2015 | 533 | 0.020 |
Why?
| | Blotting, Western | 2 | 2005 | 1201 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2381 | 0.020 |
Why?
| | Corneal Diseases | 1 | 2010 | 34 | 0.020 |
Why?
| | Organ Size | 1 | 2010 | 450 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2005 | 1711 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 2549 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2010 | 786 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 731 | 0.020 |
Why?
| | Molteno Implants | 1 | 2006 | 2 | 0.020 |
Why?
| | Nerve Crush | 1 | 2005 | 5 | 0.020 |
Why?
| | Depression, Chemical | 1 | 2005 | 22 | 0.020 |
Why?
| | Calcineurin | 1 | 2005 | 91 | 0.010 |
Why?
| | Prosthesis Design | 1 | 2006 | 322 | 0.010 |
Why?
| | Apoptosis | 2 | 2003 | 2519 | 0.010 |
Why?
| | Time Factors | 2 | 2005 | 6615 | 0.010 |
Why?
| | Caspase 7 | 1 | 2003 | 22 | 0.010 |
Why?
| | Enzyme Precursors | 1 | 2002 | 15 | 0.010 |
Why?
| | Retina | 1 | 2005 | 281 | 0.010 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2003 | 89 | 0.010 |
Why?
| | Staining and Labeling | 1 | 2002 | 143 | 0.010 |
Why?
| | Immunoblotting | 1 | 2002 | 304 | 0.010 |
Why?
| | Caspase 3 | 1 | 2003 | 242 | 0.010 |
Why?
|
|
Pantcheva's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|